Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. Among authors: peeva e. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA, Dowty ME, Page K, Vincent MS, Zhang W, Zhu L, Peeva E. Guttman-Yassky E, et al. Among authors: peeva e. J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1. J Allergy Clin Immunol. 2022. PMID: 34863853 Free article. Clinical Trial.
Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.
Peeva E, Guttman-Yassky E, Banerjee A, Sinclair R, Cox LA, Zhu L, Zhu H, Vincent M, King B. Peeva E, et al. J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13. J Am Acad Dermatol. 2022. PMID: 34915057 Free article. Clinical Trial. No abstract available.
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
Tehlirian C, Singh RSP, Pradhan V, Roberts ES, Tarabar S, Peeva E, Vincent MS, Gale JD. Tehlirian C, et al. Among authors: peeva e. J Am Acad Dermatol. 2022 Aug;87(2):333-342. doi: 10.1016/j.jaad.2022.03.059. Epub 2022 Apr 6. J Am Acad Dermatol. 2022. PMID: 35398218 Free article. Clinical Trial.
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, Kieras E, Parsons-Rich D, Menon S, Salganik M, Page K, Peeva E. Schmieder GJ, et al. Among authors: peeva e. Br J Dermatol. 2018 Jul;179(1):54-62. doi: 10.1111/bjd.16004. Epub 2018 Mar 6. Br J Dermatol. 2018. PMID: 28949012 Clinical Trial.
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS. Robinson MF, et al. Among authors: peeva e. Arthritis Rheumatol. 2020 Oct;72(10):1621-1631. doi: 10.1002/art.41316. Epub 2020 Sep 7. Arthritis Rheumatol. 2020. PMID: 32419304 Free PMC article. Clinical Trial.
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Singh RSP, Pradhan V, Roberts ES, Scaramozza M, Kieras E, Gale JD, Peeva E, Vincent MS, Banerjee A, Fensome A, Dowty ME, Winkle P, Tehlirian C. Singh RSP, et al. Among authors: peeva e. Clin Transl Sci. 2021 Mar;14(2):671-682. doi: 10.1111/cts.12929. Epub 2020 Dec 8. Clin Transl Sci. 2021. PMID: 33290616 Free PMC article. Clinical Trial.
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Landis MN, Arya M, Smith S, Draelos Z, Usdan L, Tarabar S, Pradhan V, Aggarwal S, Banfield C, Peeva E, Vincent MS, Sikirica V, Xenakis J, Beebe JS. Landis MN, et al. Among authors: peeva e. Br J Dermatol. 2022 Dec;187(6):878-887. doi: 10.1111/bjd.21826. Epub 2022 Oct 23. Br J Dermatol. 2022. PMID: 35986699 Free PMC article. Clinical Trial.
79 results